Lux Capital

Lux Capital in Nomic Bio’s US$17 million Series A financing round

Client

Lux Capital

Value

US$17 million

Service

Emerging and High Growth Companies

Date Closed

December 2021

Industry

Pharmaceuticals, Biotech & Life Sciences

Lead Office

Toronto

 

On December 8, 2021, Nomic Bio, a Montréal-based protein-measuring platform company, announced its US$17 million Series A financing round led by Lux Capital. With this financing, Nomic Bio, formerly known as Nplex Biosciences, aims to build the world’s highest throughput protein-measuring platform. They also aim to improve human health by providing scientists with the tools they need to measure proteins at high resolution.

Lux Capital is a New York-based venture capital firm. 

Osler, Hoskin & Harcourt LLP advised Lux Capital with a team consisting of Chad Bayne, Gary Marshall, and Jordana Corber-Tovel (Emerging & High Growth Companies).